Home / Resource Library / Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review

Low-Dose Anti-PD1 Immune Checkpoint Inhibitors in Relapsed/Refractory Hodgkin Lymphoma: A Systematic Review

Study investigated low doses of PD-1 inhibitors for treatment of relapsed Hodgkin lymphoma.